Overview

To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis

Status:
Recruiting
Trial end date:
2022-12-15
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study in subjects with moderate to severe plaque psoriasis.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Pharmaceutical Industries Limited